Table 1.
Patient demographics and baseline characteristics.
| SML (n = 44) | TCL (n = 44) | t or χ2 or z | P1 | P2 | |
|---|---|---|---|---|---|
| Sex | |||||
| Male, n (%) | 35 (79.55) | 42 (95.45) | |||
| Female, n (%) | 9 (20.45) | 2 (4.55) | 5.091 | 0.024* | |
| Age (years) | |||||
| Mean ± SD | 44.41 ± 8.71 | 44.68 ± 6.77 | 0.164 | 0.87 | |
| Median (IQR) | 44 (39–51.5) | 45 (40–48) | 0.322 | 0.748 | |
| Duration (weeks) | |||||
| Mean ± SD | 10.50 ± 8.22 | 10.20 ± 8.22 | −0.169 | 0.867 | |
| Median (IQR) | 7.5 (4–18) | 6.5 (4–18) | −0.324 | 0.746 | |
| BCVA (ETDRS letters) | |||||
| Mean ± SD | 76.60 ± 7.00 | 77.84 ± 7.70 | 0.159 | 0.874 | |
| Median (IQR) | 77 (73–80) | 77.5 (72–82) | 0.209 | 0.835 | |
| CRT (μm) | |||||
| Mean ± SD | 398.50 ± 92.92 | 407.49 ± 133.55 | 0.367 | 0.715 | |
| Median (IQR) | 381 (332–445.75) | 374 (324.5–458) | −0.142 | 0.887 | |
| Leakage location | |||||
| Ring 2, n (%) | 35 (79.55) | 34 (77.27) | |||
| Ring 3, n (%) | 9 (20.45) | 10 (22.73) | 0.067 | 0.796 | |
| Leakage point | |||||
| Single, n (%) | 35 (79.55) | 35 (79.55) | |||
| Multiple, n (%) | 9 (20.45) | 9 (20.45) | 0 | 1 | |
| Primary/recurrent | |||||
| Primary, n (%) | 41 (93.18) | 37 (84.09) | 1.805 | 0.179 | |
| Recurrent, n (%) | 3 (6.82) | 7 (15.91) | |||
| Prior laser treatment n (%) | 1 (2.27) | 4 (9.09) | 0.848 | 0.357 | |
| Systemic steroid n (%) | 0 (0) | 2 (4.55) | 0.512 | 0.474 | |
Full analysis set. P1 represented the P value of the independent t-test result or χ2. P2 represented the P value of the Wilcoxon rank-sum (Mann–Whitney) test
SML subthreshold micropulse laser, TCL threshold conventional laser, SD standard deviation, IQR interquartile range, BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, CRT central retinal thickness
*Significant P value (<0.05)